Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.59 |
| ▸ | TGFBR1 | P36897 | 15/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194489 | 0.86 | ACACB (0.71) | ACACBTGFBR1HDAC3HDAC4HDAC1 | |
| SCHEMBL13538761 | 0.85 | ACACB (0.64) | ACACBTGFBR1HDAC3HDAC4HDAC1 | |
| SCHEMBL13538768 | 0.82 | LMNA (0.52) | ACACBHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10194537 | 0.81 | SFRP1 (0.53) | ACACBTGFBR1 | |
| SCHEMBL10194498 | 0.80 | ADAM17 (0.51) | ACACBTGFBR1F10 | |
| SCHEMBL10194548 | 0.79 | SFRP1 (0.56) | ACACBTGFBR1 | |
| SCHEMBL6786293 | 0.76 | ACACB (0.53) | ACACBTGFBR1 | |
| SCHEMBL2333096 | 0.76 | STS (0.45) | ACACB | |
| SCHEMBL10194497 | 0.76 | ADAM17 (0.55) | ACACBTGFBR1 | |
| SCHEMBL8580938 | 0.76 | ACACB (0.48) | ACACBTGFBR1BCHEF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513237-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-07-12 | — | — | US | disclosed |
| US-8163733-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-24 | — | — | US | disclosed |
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-16 | — | — | US | disclosed |
| US-7767679-B2 | Sulfonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234353-A1 | SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | ACACB 1340/4885TGFBR1 1446/4885HDAC3 2/4885 |
| US-20120178741-A1 | Sulfonylamino-Derivatives As Novel Inhibitors Of Histone Deacetylase | HDAC1, HDAC3, HDAC11 | ACACB 1340/4885TGFBR1 1446/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.